Home Stocks Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd

The live share price of Glenmark Pharmaceuticals Ltd (GLENMARK) as on 08 May 9:59am is ₹1,021.5 from NSE/BSE.

GLENMARK NSE

₹1,021.5 ▲0.57% (5.75)

As on May 08, 2024 03:29 PM IST

How do you feel today about Glenmark Pharmaceuticals Ltd?

Bearish or

Bullish

Bearish or

Bullish

Key Metrics

PE Ratio

-42.05

PB Ratio

3.04

Dividend Yield

0.24%

Sector PB

5.98

Sector PE

49.67

Sector Div Yld

0.58%

Dividend Yield

Dividend per share for the most recent financial year divided by the close price

About

Sector

Health Care

Industry

Pharmaceuticals

Market Cap

Midcap, ₹29,926 Cr

Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).

The following charts display the financial performance of the Glenmark Pharmaceuticals Ltd (GLENMARK) stock, including the year-on-year Income Statement , Balance Sheet , Cash Flow Statement and Shareholding pattern.

Furthermore, under the Peers section, you can find stocks that are similar to Glenmark Pharmaceuticals Ltd (GLENMARK), and their live stock price and performance at a glance. Click on any peer stock to navigate to that stock’s live price page.

✅ If you’re new to investing in the stock market, and/or are unsure about your investment options, you can explore smallcases.

A smallcase is a readymade stock/ETF portfolio (also known as a stock basket) that is based on an investment idea, theme or strategy. Examples of popular smallcases include All Weather Investing , Equity and Gold , Top 100 Stocks , Green Energy and Value & Momentum.

All smallcases are created and managed by SEBI-registered investment experts.

To invest in smallcases, all you need is a demat/trading account. You retain complete ownership of the smallcase’s constituent stocks or ETFs, as they are directly credited to your broking account. You can choose from over 500+ smallcases across 180+ smallcase managers to start your investment journey.

Sector

Health Care

Industry

Pharmaceuticals

Market Cap

Midcap, ₹29,926 Cr

Financials

Income Statement

(INR)		Y/Y Change
Revenue	13,306 Cr	+6.7%
Operating Expense	1,816 Cr	+9.6%
Net Income	297 Cr	-68.44%
Net Profit Margin	2.23%	-70.46%
Earning Per Share	10	-68.45%
EBITDA	1,829 Cr	-17.82%

Balance sheet

(INR)		Y/Y Change
Cash & short-term Inv	1,469 Cr	+4.12%
Total Assets	19,328 Cr	+13.35%
Total Liabilities	9,489 Cr	+24.64%
Total Equity	9,839 Cr	+4.25%
Shares Outstanding	28.22 Cr	+0.01%
Price to Book	1.33	-1.65%
Return on Assets	1.63%	-71.75%
Return on Capital	12.38 Cr	-32.83%

Cash Flows

(INR)		Y/Y Change
Net Income	297 Cr	-68.44%
Cash from Operations	625 Cr	-43.59%
Cash from Investing	-515 Cr	+63.25%
Cash from Financing	-77 Cr	-85.12%
Net Change in Cash	32 Cr	-88.07%
Free Cash Flow	17 Cr	-94.47%

Shareholding Pattern

Total Promoter Holding

46.64%

Unpledged

Foreign Institutions

21.38%

Foreign Institutions

Retail & Others

18.61%

Retail & Others

Other Parties

Other Domestic Institutions

2.81%

Insurance Firms

Others

Mutual Funds

10.55%

Mutual Funds

Peers

SUNPHARMA

Sun Pharmaceutical Industries Ltd

PE Ratio

40.92

1Y Return

▲57.55%

CIPLA

Cipla Ltd

PE Ratio

30.92

1Y Return

▲48.63%

DRREDDY

Dr Reddy's Laboratories Ltd

PE Ratio

18.77

1Y Return

▲27.52%

ZYDUSLIFE

Zydus Lifesciences Ltd

PE Ratio

33.43

1Y Return

▲86.69%

Latest News

Glenmark Pharma Gets USFDA Nod For Generic Anti-inflammatory Drug

1 week ago on Bloomberg Quint

Change since news ▼-INF%

Glenmark Therapeutics Inc, USA will distribute the drug in the US market, the drug maker said.

Glenmark Recalls 6,528 Bottles Of Blood Pressure Drug In US

3 weeks ago on Bloomberg Quint

Change since news ▼-INF%

The affected lot has been produced in India and is being recalled by New Jersey-based Glenmark Pharmaceuticals Inc for ‘failed dissolution specifications’, the USFDA said.

Buy Glenmark Pharmaceuticals; target of Rs 1266: KR Choksey

1 month ago on Moneycontrol

Change since news ▼-INF%

KR Choksey is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1266 in its research report dated April 05, 2024.

FAQs on Glenmark Pharmaceuticals Ltd

How to buy Glenmark Pharmaceuticals Ltd stocks?

You can easily buy the stocks/shares of Glenmark Pharmaceuticals Ltd (GLENMARK) through either a broker or a financial institution by opening a Demat & Trading account online via smallcase.

What is the Share Price of Glenmark Pharmaceuticals Ltd?

The stock price of Glenmark Pharmaceuticals Ltd as on 08 May 2024 is ₹1,021.5

What is the 52-week High and Low of Glenmark Pharmaceuticals Ltd?

The 52-week high and low of Glenmark Pharmaceuticals Ltd (GLENMARK) is ₹1,098 and ₹551.

What is the PE and PB ratio of Glenmark Pharmaceuticals Ltd?

The P/E (price-to-earnings) and P/B (price-to-book) ratios of Glenmark Pharmaceuticals Ltd are -42.05 and 3.04 respectively.

What are the peers or stocks similar to Glenmark Pharmaceuticals Ltd?

The peers or stocks similar to Glenmark Pharmaceuticals Ltd are Sun Pharmaceutical Industries Ltd, Cipla Ltd, Dr Reddy's Laboratories Ltd, Zydus Lifesciences Ltd and many others. smallcase also offers over 200 readymade stock baskets managed by 180+ SEBI-registered investment experts. These stock portfolios are based on a theme, idea or strategy. You can use smallcase to start investing in diversified stock baskets.

Which sector does Glenmark Pharmaceuticals Ltd belong to?

Glenmark Pharmaceuticals Ltd (GLENMARK) belongs to the Pharmaceuticals sector.

What is the Market Cap of Glenmark Pharmaceuticals Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Glenmark Pharmaceuticals Ltd (GLENMARK) is ₹29,926 Cr as of 08 May 2024

Can't decide whether or not to buy Glenmark Pharmaceuticals Ltd stocks? ⭐️

Worry no more! smallcase offers readymade stock baskets/portfolios that are based on an theme, idea or strategy. You can choose from more than 500+ stock portfolios managed by 180+ SEBI-registered investment experts.

Dislaimer: This platform is intended for informational purposes only and is not intended to provide investment advice. The stock prices displayed are delayed and may not reflect the most current market conditions. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. You can also consider consulting a financial advisor before making any investment decisions. Smallcase Technologies Private Limited shall not be responsible for any losses that may occur as a result of using this platform.